PeMa Quadrant · 1st edition · October 3, 2025

    Agentic AI Use Cases in Life Sciences

    Agentic AI refers to autonomous AI systems capable of making decisions, executing complex workflows, and adapting to changing environments with minimal human intervention. Unlike traditional AI, Agentic AI combines reasoning, planning, and execution to automate processes and generate actionable insights, making it particularly suited to the data-intensive and highly regulated nature of the life sciences industry.

    Across the pharmaceutical value chain, Agentic AI is being adopted in drug discovery, clinical trials, pharmacovigilance, regulatory affairs, manufacturing, and supply chain management to accelerate research, improve operational efficiency, support compliance, and enhance decision-making. Emerging applications such as biomarker discovery, disease modeling, diagnostics, and multimodal patient data integration are also advancing precision medicine and personalized therapies.

    As adoption expands, Agentic AI is enabling life sciences organizations to streamline research and operations, accelerate innovation, and improve patient outcomes, positioning it as a key technology for next-generation pharmaceutical and healthcare transformation.

    Request access

    Subscribers only

    Vendors evaluated
    27
    Leaders
    11
    Seasoned
    8
    Growth
    1
    Challengers
    7

    First edition of this PeMa Quadrant.

    The PeMa Quadrant · Agentic AI Service Providers

    Where 27 vendors landed in 2025

    1. 1Filter by band
    2. 2Open a vendor
    3. 3Compare or shortlist
    SeasonedLeadersChallengersGrowthAaysAkaike Technologies ArtivaticBlend360C5iCentificChetuDentsuEvalueserveEY Global Delivery Services LLP FujitsuIndus Net TechnologiesInfoCeptsIntelekt AIJK TechKonverge AIMathCoSenzcraftSG AnalyticsStraiveStratLyticsThink360.aiTiger AnalyticsUSEReadyTechnology & Service Maturity (Ma) →Market Penetration (Pe) →
    Positions are relative to the vendors evaluated in this edition.

    What the report finds

    5 shifts buyers should know

    Open any finding for the analyst's explanation.

    In the full report

    • Every vendor profile and score
    • Strengths and cautions by vendor
    • The full-resolution quadrant
    1. 01Agentic AI adoption in life sciences is in its early stages, with potential in drug discovery, clinical trials, and regulatory compliance.
    2. 02Agentic AI is anticipated to drive hyper-personalized drug development and enable real-time optimization of drug discovery and clinical trials.
    3. 03Life science companies face challenges in adopting Agentic AI, including data privacy concerns and ensuring regulatory compliance.
    4. 04Agentic AI is transforming life sciences by accelerating drug discovery, clinical trials, and regulatory workflows.
    5. 05Multi-agent systems automate reporting, ensure data integrity, and streamline compliance documentation in life sciences.

    Abstract

    The report on Agentic AI use cases in life sciences explores the transformative potential of autonomous AI systems in the sector.

    Agentic AI, characterized by its ability to operate independently and adapt to environments without constant human intervention, is being increasingly adopted across the pharmaceutical value chain. Key applications include drug discovery, clinical trials, pharmacovigilance, and regulatory compliance. The report highlights that while the adoption of Agentic AI is still in its early stages, it shows promise in enhancing efficiency, decision-making, and operational agility. Leading pharmaceutical companies are exploring scalable AI solutions to improve drug discovery processes, optimize clinical trials, and ensure regulatory compliance. The report also discusses the challenges faced by life sciences companies in implementing Agentic AI, such as data privacy concerns, integration of heterogeneous datasets, and maintaining transparency in AI-driven decisions. Overall, the adoption of Agentic AI is poised to transform how pharmaceutical companies innovate, operate, and deliver therapies, positioning AI as a crucial enabler of next-generation life sciences innovation.

    Methodology

    How vendors were scored

    The research was conducted by evaluating Agentic AI use cases across the life sciences value chain.

    X axis

    Market Penetration (Pe)

    • Delivery scale
    • Financial health
    • Customer mindshare

    Y axis

    Technology & Service Maturity (Ma)

    • Technical innovation
    • Value realisation
    • DataOps depth

    The research was conducted by evaluating Agentic AI use cases across the life sciences value chain. The methodology involved analyzing data from leading pharmaceutical companies and service providers to assess the maturity and potential of Agentic AI applications. The evaluation framework considered parameters such as complexity, scalability, need for autonomy, and regulatory compliance. Case studies and industry trends were examined to provide insights into the current and future impact of Agentic AI in life sciences.

    Full report · PDF

    Get the vendor profiles, scores and full quadrant

    Free with a work email. The PDF arrives in your inbox.

    Subscribers-only report

    This report is available to subscribers. Contact us to request access.

    Request subscriber access

    For vendors

    Not in this study?

    Every PeMa Quadrant starts with an open RFI. See which studies are open and when the next edition of this market starts.

    FAQ

    Questions about this report

    Agentic AI refers to a class of artificial intelligence systems designed to operate autonomously, make decisions, and adapt to environments without constant human intervention. Unlike traditional AI, Agentic systems execute complex workflows, analyze large datasets, and optimize processes in real time.

    In drug discovery, Agentic AI is used for target identification, compound screening, and mechanism modeling. It enables autonomous research agents to conduct and optimize scientific research, and AI-enabled solutions tailor treatments to individual patient profiles, accelerating the drug discovery process.

    Life science companies face challenges such as data privacy and security concerns, integrating heterogeneous datasets, ensuring regulatory compliance, maintaining transparency in AI-driven decisions, and balancing human oversight with automation. High computational costs and model interpretability also pose challenges.